Our description of AD-type tau as a prominent pathology in LRRK2 mutation carriers suggests that tau hyperphosphorylation may be an important component of LRRK2-related pathogenesis, and further investigation of the relationship between LRRK2 kinase activity and tau pathology in animal models is warranted. Here, MAPT is linked to Alzheimer disease.